Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7172 + AG + SHR-1316
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HRS-7172 + AG + SHR-1316 is an investigational combination regimen under development by Jiangsu Hengrui Pharmaceuticals for the treatment of advanced solid tumors, specifically pancreatic cancer harboring RAS mutations or amplifications. The regimen combines three therapeutic modalities: HRS-7172, an oral small molecule pan-RAS inhibitor; AG, a standard chemotherapy doublet consisting of nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine; and SHR-1316 (adebrelimab), a humanized IgG4 monoclonal antibody targeting PD-L1. This triplet combination is designed to synergistically inhibit oncogenic RAS signaling, induce cytotoxic tumor cell death, and block immune checkpoint pathways to enhance T-cell-mediated antitumor responses.
- Other names
- HRS-7172 + AG + adebrelimabHRS-7172 + nab-paclitaxel + gemcitabine + adebrelimabHRS-7172 + nab-paclitaxel + gemcitabine + SHR-1316
02
Targets
HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HRS-7172 + AG + SHR-1316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7172 + AG + SHR-1316.